Novartis' Swiss Shuffle: A Glimpse into Big Pharma's Future?
The recent announcement from Novartis AG that it plans to relocate laboratory activities and cease small scale biologics production at its Kleinbasel site in Basel, Switzerland, has sparked concerns about the potential impact on employees and the region.
However, a closer examination of the company's strategy reveals a more nuanced story about the future of big pharma.